Rubius Therapeutics Inc. (RUBY) and CTI BioPharma Corp. (NASDAQ:CTIC) Comparison side by side

We are contrasting Rubius Therapeutics Inc. (NASDAQ:RUBY) and CTI BioPharma Corp. (NASDAQ:CTIC) on their profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation. They both are Biotechnology companies, competing one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Rubius Therapeutics Inc. N/A 0.00 107.36M -1.12 0.00
CTI BioPharma Corp. 16.08M 3.31 36.11M -0.62 0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Rubius Therapeutics Inc. and CTI BioPharma Corp.


Table 2 has Rubius Therapeutics Inc. and CTI BioPharma Corp.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Rubius Therapeutics Inc. 0.00% -52.6% -26.4%
CTI BioPharma Corp. -224.56% -61.3% -40.4%

Insider & Institutional Ownership

The shares of both Rubius Therapeutics Inc. and CTI BioPharma Corp. are owned by institutional investors at 94.5% and 61% respectively. Insiders owned 8.4% of Rubius Therapeutics Inc. shares. Insiders Competitively, owned 0.1% of CTI BioPharma Corp. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Rubius Therapeutics Inc. 3.88% -13.94% 14.66% 0.7% 0% -1.74%
CTI BioPharma Corp. -11.78% -18.44% -7.38% -50.87% -79.41% 14.52%

For the past year Rubius Therapeutics Inc. had bearish trend while CTI BioPharma Corp. had bullish trend.


CTI BioPharma Corp. beats on 5 of the 9 factors Rubius Therapeutics Inc.

Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria. It is also developing RTX-212 and RTX-4-1BBL for treatment of solid tumors; RTX-212 for hematological cancer; RTX-aAPC to treat solid and hematological cancers; and other product candidates for autoimmune disorders. The company was founded in 2013 and is based in Cambridge, Massachusetts.

CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis. In addition, it is developing Tosedostat, an oral once-daily aminopeptidase inhibitor that is in Phase II clinical trials for the treatment of acute myeloid leukemia. The company has license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier; development, commercialization, and license agreement with Baxter International Inc.; agreement with the University of Vermont, BIO Pte Ltd., Gynecologic Oncology Group, and PG-TXL Company, L.P; and license agreement with Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.